Form 4: Context Therapeutics Inc.: Chief Legal Officer Acquires Stock Options

Alex C. Levit, Chief Legal Officer of Context Therapeutics Inc., acquired stock options for 349,900 shares at an exercise price of $0.81 on February 13, 2025.

Summary

• On February 13, 2025, Alex C. Levit, the Chief Legal Officer and Corporate Secretary of Context Therapeutics Inc., acquired stock options.
• The options grant the right to buy 349,900 shares of Context Therapeutics Inc. common stock at an exercise price of $0.81 per share.
• The options vest over a four-year period, with 25% vesting on February 13, 2026, and the remainder vesting in equal monthly installments over the subsequent three years, contingent upon continued service with the company.
• Following the transaction, Levit directly owns 349,900 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither inherently positive nor negative.

Industry Context

This filing is a routine disclosure of stock option grants to a company executive, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Stakeholder Impact

• The stock option grant may incentivize the Chief Legal Officer to work towards increasing shareholder value.
• The vesting schedule ensures continued service with the company.

Key Dates